Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Neoplasms
Interventions
DRUG

carboplatin + SU011248 (sunitinib) + paclitaxel

AUC of 6 mg\*min/mL administered as a 30-minute infusion, every 21 days for 4 cycles or until progression/unacceptable toxicity. 25 mg, 37.5 mg, or 50 mg (depending on the dose level assigned) orally taken every day or for 2 weeks and 1 week off without for 4 cycles or until progression/unacceptable toxicity. 175 mg/m2, 200 mg/m2, or 225 mg/m2 (depending on the dose level assigned), administered as a 3-hour infusion every 21 days for 4 cycles or until progression/unacceptable toxicity.

Trial Locations (4)

19111

Pfizer Investigational Site, Philadelphia

48201

Pfizer Investigational Site, Detroit

53792

Pfizer Investigational Site, Madison

77030

Pfizer Investigational Site, Houston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY